Oryzon Genomics disclosed that its shares fell 11% on the day the company launched an accelerated private placement aimed at raising up to €10 million, with the amount potentially increasing to €15 million depending on investor demand. The board approved a capital increase through the issuance of new ordinary shares, explicitly excluding pre‑emptive subscription rights. The placement is being executed privately within the European Economic Area by Singular Bank and Invest Securities.
The proceeds from the placement are earmarked to strengthen Oryzon’s balance sheet and to accelerate its acute myeloid leukemia (AML) programme. In addition, Oryzon entered into a share subscription agreement with Spain’s Social Impact Fund (FIS), which is managed by the development finance company COFIDES. Under this agreement, the fund has committed to subscribe for €25 million of newly issued shares in a future capital increase, subject to certain conditions. The commitment applies to any capital increase undertaken within six months of signing the agreement, a period that may be extended by mutual consent.
If the conditions are satisfied and the investment proceeds, Oryzon intends to allocate the funds to research and development across central nervous system disorders, oncology, and hematology, with a minimum of 40% dedicated to developing treatments for unmet mental‑health needs, notably its borderline personality disorder programme and other psychiatric conditions.
Separately, the board unanimously resolved to propose an amendment to the company’s corporate purpose at the forthcoming shareholders’ meeting, explicitly stating that the purpose is to improve quality of life through medicines for unmet needs in mental health, cancer, and other serious diseases. The amendment would require a 75% majority to be adopted.
The capital increase is expected to be fully paid up before the market opens on 2 July 2026, with the new shares admitted to trading that same day and commencing regular trading on 3 July 2026.